Discovery and characterization of potent broadly neutralizing antibodies from human survivors of severe fever with thrombocytopenia syndrome.

IF 9.7 1区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL EBioMedicine Pub Date : 2025-01-01 Epub Date: 2024-12-06 DOI:10.1016/j.ebiom.2024.105481
Shuo Zhang, Hang Shang, Shuo Han, Jiachen Li, Xuefang Peng, Yongxiang Wu, Xin Yang, Yu Leng, Fengze Wang, Ning Cui, Lingjie Xu, Hongkai Zhang, Yu Guo, Xiaoyu Xu, Nan Zhang, Wei Liu, Hao Li
{"title":"Discovery and characterization of potent broadly neutralizing antibodies from human survivors of severe fever with thrombocytopenia syndrome.","authors":"Shuo Zhang, Hang Shang, Shuo Han, Jiachen Li, Xuefang Peng, Yongxiang Wu, Xin Yang, Yu Leng, Fengze Wang, Ning Cui, Lingjie Xu, Hongkai Zhang, Yu Guo, Xiaoyu Xu, Nan Zhang, Wei Liu, Hao Li","doi":"10.1016/j.ebiom.2024.105481","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging tick-borne phlebovirus that causes viral hemorrhagic fever. Pandemic concerns have arisen due to the increased human-to-human transmission and high mortality rate, highlighting the urgent need for specific therapeutics.</p><p><strong>Methods: </strong>Our observational study characterized the memory B cell response to natural SFTSV infection in four survivors. Monoclonal antibodies (mAbs) targeting the SFTSV glycoprotein N (Gn) were isolated and tested for in vitro neutralizing activities and effects on virus binding. Structural analysis was performed to identify neutralizing epitopes recognized by the mAbs. Prophylactical and therapeutical protections were evaluated using a lethal SFTSV infection model.</p><p><strong>Findings: </strong>The selected mAbs exhibiting neutralizing activity primarily originate from the IGHV5-51 and IGHV3-30 germlines and target four distinct antigenic sites on SFTSV Gn. These elite mAbs effectively blocked the interaction between Gn and the cell receptor, preventing infections from five phylogenetically distinct SFTSV clades. Structural analysis revealed a novel neutralizing epitope located within SFTSV Gn domain I recognized by the elite mAbs. In mice of lethal infections with different SFTSV strains, administering a low dose of elite mAbs significantly improved survival rates in both prophylactic and therapeutic settings.</p><p><strong>Interpretation: </strong>This study identifies potent broadly neutralizing antibodies that holds promise for use in humans against SFTSV infection and highlights inhibition of receptor binding as a crucial mechanism for effective antibody-mediated neutralization against phleboviruses.</p><p><strong>Funding: </strong>The National Key Research and Development Plan of China (2018YFE0200401, 2022YFC2303300), National Natural Science Foundation of China (81825019), China Postdoctoral Science Foundation (2023M741824).</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"111 ","pages":"105481"},"PeriodicalIF":9.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11665701/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EBioMedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ebiom.2024.105481","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/6 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging tick-borne phlebovirus that causes viral hemorrhagic fever. Pandemic concerns have arisen due to the increased human-to-human transmission and high mortality rate, highlighting the urgent need for specific therapeutics.

Methods: Our observational study characterized the memory B cell response to natural SFTSV infection in four survivors. Monoclonal antibodies (mAbs) targeting the SFTSV glycoprotein N (Gn) were isolated and tested for in vitro neutralizing activities and effects on virus binding. Structural analysis was performed to identify neutralizing epitopes recognized by the mAbs. Prophylactical and therapeutical protections were evaluated using a lethal SFTSV infection model.

Findings: The selected mAbs exhibiting neutralizing activity primarily originate from the IGHV5-51 and IGHV3-30 germlines and target four distinct antigenic sites on SFTSV Gn. These elite mAbs effectively blocked the interaction between Gn and the cell receptor, preventing infections from five phylogenetically distinct SFTSV clades. Structural analysis revealed a novel neutralizing epitope located within SFTSV Gn domain I recognized by the elite mAbs. In mice of lethal infections with different SFTSV strains, administering a low dose of elite mAbs significantly improved survival rates in both prophylactic and therapeutic settings.

Interpretation: This study identifies potent broadly neutralizing antibodies that holds promise for use in humans against SFTSV infection and highlights inhibition of receptor binding as a crucial mechanism for effective antibody-mediated neutralization against phleboviruses.

Funding: The National Key Research and Development Plan of China (2018YFE0200401, 2022YFC2303300), National Natural Science Foundation of China (81825019), China Postdoctoral Science Foundation (2023M741824).

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
从发热伴血小板减少综合征的人类幸存者身上发现和鉴定强效广泛中和抗体。
背景:发热伴血小板减少综合征病毒(SFTSV)是一种新出现的蜱传白蛉病毒,可引起病毒性出血热。由于人与人之间的传播增加和死亡率高,引起了对大流行的关注,突出了对特定治疗方法的迫切需要。方法:我们的观察性研究描述了4名幸存者对SFTSV自然感染的记忆B细胞反应。分离了针对SFTSV糖蛋白N (Gn)的单克隆抗体(mab),并检测了其体外中和活性和对病毒结合的影响。进行结构分析以鉴定单克隆抗体识别的中和表位。使用致死性SFTSV感染模型评估预防和治疗保护。结果:所选择的单克隆抗体具有中和活性,主要来自IGHV5-51和IGHV3-30种系,靶向SFTSV Gn上的四个不同抗原位点。这些精英单克隆抗体有效地阻断了Gn和细胞受体之间的相互作用,防止了5种不同系统发育的SFTSV分支的感染。结构分析显示一个新的中和表位位于SFTSV Gn结构域1,被精英单克隆抗体识别。在不同SFTSV毒株致死性感染的小鼠中,给予低剂量的精英单抗显著提高了预防和治疗环境下的存活率。解释:本研究确定了有效的广泛中和抗体,有望用于人类对抗SFTSV感染,并强调了受体结合的抑制是抗体介导的有效中和静脉病毒的关键机制。国家重点研发计划项目(2018YFE0200401, 2022YFC2303300),国家自然科学基金项目(81825019),中国博士后科学基金项目(2023M741824)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
文献相关原料
公司名称
产品信息
索莱宝
balanced salt solution
索莱宝
stop solution
索莱宝
TMB
索莱宝
Triton X-100
索莱宝
TMB
来源期刊
EBioMedicine
EBioMedicine Biochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology
CiteScore
17.70
自引率
0.90%
发文量
579
审稿时长
5 weeks
期刊介绍: eBioMedicine is a comprehensive biomedical research journal that covers a wide range of studies that are relevant to human health. Our focus is on original research that explores the fundamental factors influencing human health and disease, including the discovery of new therapeutic targets and treatments, the identification of biomarkers and diagnostic tools, and the investigation and modification of disease pathways and mechanisms. We welcome studies from any biomedical discipline that contribute to our understanding of disease and aim to improve human health.
期刊最新文献
Cellular blueprint of healthy and diseased human epiglottis and subglottis-a study of the Canadian Airways Research (CARE) group. Cohort-level clinical trajectory and molecular landscape of idiopathic subglottic stenosis for precision laryngology-a study of the Canadian airways research (CARE) group. Dynamics of gut resistome and mobilome in early life: a meta-analysis. Functional characterisation of missense ceruloplasmin variants and real-world prevalence assessment of Aceruloplasminemia using population data. Rapid high-throughput sequencing: a game-changer for timely addressing infectious diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1